Phase I Study to Investigate Safety, Pharmacokinetics and Preliminary Efficacy Profile of Sorafenib (BAY 43-9006) in Combination With S-1 Plus CDDP in Asian Patients With Unresectable / Recurrent Gastric Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety and pharmacokinetics
20 weeks after start of treatment
Yes
Bayer Study Director
Study Director
Bayer
Japan: Ministry of Health, Labor and Welfare
12931
NCT00663741
May 2008
April 2010
Name | Location |
---|